Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 44Triple Negative Breast Neoplasms 20Breast Neoplasms 16Carcinoma, Non-Small-Cell Lung 14Neoplasm Metastasis 10Lung Neoplasms 10Squamous Cell Carcinoma of Head and Neck 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Neoplasms 6Adenocarcinoma 6Cholangiocarcinoma 5Stomach Neoplasms 4Gallbladder Neoplasms 4Esophageal Squamous Cell Carcinoma 4Esophageal Neoplasms 4Biliary Tract Neoplasms 4Uterine Cervical Neoplasms 3Recurrence 3Pancreatic Adenocarcinoma 3Ovarian Neoplasms 3Head and Neck Neoplasms 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Colorectal Neoplasms 3Small Cell Lung Carcinoma 2Sarcoma 2Rectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Pancreatic Ductal 2Carcinoma, Hepatocellular 2

Interventions

Gemcitabine 3130-nm albumin-bound paclitaxel 2Taxes 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Pancreatic Ductal Adenocarcinoma × Albumin-Bound Paclitaxel × 1 year × Clear all
NCT06904378 2026-05-19

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Washington University School of Medicine

Phase 1/2 Recruiting
61 enrolled
Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡